Experimental pancreatic cancer drug daraxonrasib doubles survival in advanced cases

An experimental pancreatic cancer drug called daraxonrasib has been shown to “double survival in patients with advanced stages of the disease,” said NBC News. In the latest phase of the clinical trials, daraxonrasib as a “targeted medicine delivered a dramatic improvement in overall survival in patients with previously treated metastatic pancreatic cancer compared to standard of care chemotherapy,” said Revolution Medicines, the creator of the drug.

Unlike other cancer treatments, the drug’s side effects are milder and more manageable. “Almost all patients do experience some adverse effects, with the most common being a rash that occurs in the majority of patients,” David Hong, a senior researcher at the University of Texas MD Anderson Cancer Center, said to Reuters. “But those effects are manageable in most patients, and the benefits significantly outweigh those adverse effects,” Hong said.